Literature DB >> 26174685

Intraethnic variation in steroid-5-alpha-reductase polymorphismsin prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment.

Luis Alberto Henríquez-Hernández1, Almudena Valenciano, Palmira Foro-Arnalot, María Jesús Álvarez-Cubero, José Manuel Cozar, José Francisco Suárez-Novo, Manel Castells-Esteve, Pablo Fernández-Gonzalo, Belén De-Paula-Carranza, Montse Ferrer, Ferrán Guedea, Gemma Sancho-Pardo, Jordi Craven-Bartle, María José Ortiz-Gordillo, Patricia Cabrera-Roldán, Estefanía Herrera-Ramos, Carlos Rodríguez-Gallego, Pedro C Lara.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26174685     DOI： 10.1007/s12041-015-0511-3

Source DB:  PubMed          Journal:  J Genet        ISSN： 0022-1333            Impact factor:   1.166


× No keyword cloud information.
  23 in total

1.  The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies.

Authors:  S U Yasuda; L Zhang; S-M Huang
Journal:  Clin Pharmacol Ther       Date:  2008-07-09       Impact factor: 6.875

2.  Effect of dutasteride on the risk of prostate cancer.

Authors:  Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster
Journal:  N Engl J Med       Date:  2010-04-01       Impact factor: 91.245

Review 3.  Prostatic growth: new insights into hormonal regulation.

Authors:  J D McConnell
Journal:  Br J Urol       Date:  1995-07

4.  Endocrine-induced regression of cancers.

Authors:  C Huggins
Journal:  Cancer Res       Date:  1967-11       Impact factor: 12.701

5.  Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.

Authors:  Mark A Titus; Christopher W Gregory; O Harris Ford; Michael J Schell; Susan J Maygarden; James L Mohler
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

6.  Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.

Authors:  Sara Lindström; Fredrik Wiklund; Hans-Olov Adami; Katarina Augustsson Bälter; Jan Adolfsson; Henrik Grönberg
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

Review 7.  Pharmacogenetics, pharmacogenomics, and individualized medicine.

Authors:  Qiang Ma; Anthony Y H Lu
Journal:  Pharmacol Rev       Date:  2011-03-24       Impact factor: 25.468

8.  SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.

Authors:  Christine Neslund-Dudas; Cathryn H Bock; Kristin Monaghan; Nora L Nock; James J Yang; Andrew Rundle; Deliang Tang; Benjamin A Rybicki
Journal:  Prostate       Date:  2007-11-01       Impact factor: 4.104

9.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

Review 10.  Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia.

Authors:  Gerald L Andriole; Roger Kirby
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096
View more
  1 in total

1.  Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population.

Authors:  L A Henríquez-Hernández; A Valenciano; P Foro-Arnalot; M J Álvarez-Cubero; J M Cozar; J F Suárez-Novo; M Castells-Esteve; P Fernández-Gonzalo; B De-Paula-Carranza; M Ferrer; F Guedea; G Sancho-Pardo; J Craven-Bartle; M J Ortiz-Gordillo; P Cabrera-Roldán; J I Rodríguez-Melcón; E Herrera-Ramos; C Rodríguez-Gallego; P C Lara
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-01-12       Impact factor: 5.554
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.